Beatriz Cristina Weidle Vuaden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Beatriz Cristina Weidle Vuaden has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Anna Clara Machado Colucci
Laboratory of Memory Dysfunctions, Department of Physiology, Institute for Basic Health Sciences, Federal University of Rio Grande Do Sul, Porto Alegre, Brazil
2 shared publications - Antonio Waldo Zuardi
National Institute of Science and Technology for Translational Medicine (INCT-TM), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brasília, Brazil
2 shared publications - Jaime Eduardo Cecilio Hallak
Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14040-900, Brazil
2 shared publications - José Alexandre S. Crippa
Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
2 shared publications - Layza Kowalski
Laboratory of Memory Dysfunctions, Department of Physiology, Institute for Basic Health Sciences, Federal University of Rio Grande Do Sul, Porto Alegre, Brazil
2 shared publications - Maria Noêmia Martins de Lima
Laboratory of Memory Dysfunctions, Department of Physiology, Institute for Basic Health Sciences, Federal University of Rio Grande Do Sul, Porto Alegre, Brazil
2 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Springer Nature in Neurotoxicity Research
- Vol. 44 (5) , 48
Differential Effects of Cannabidiol and Cannabigerol on Cognition, Neuroinflammation, and Blood–Brain Barrier Integrity in a Rat Model of Iron Overload
Iron is an essential micronutrient for brain development, participating in mitochondrial respiration, myelination, and neurotransmitter synthesis. However, previous studies have demonstrated that excessive iron during early postnatal life induces oxidative reactions, leading to mitochondrial dysfunction and synaptic failure. These alterations compromise energy metabolism and neuronal integrity, contributing to long-lasting cognitive dysfunction and increased brain vulnerability later in life. This study evaluated the effects of cannabidiol (CBD) and cannabigerol (CBG) on behavioral, neuroinflammatory, and blood-brain barrier (BBB) outcomes in rats exposed to early-life iron overload. Male Wistar rats received iron carbonyl (30 mg/kg, intragastrically) from postnatal day 12 to 14. At three months of age, they were treated intraperitoneally with CBD, CBG (both at 10 mg/kg), or vehicle for 21 days. Cognitive performance was assessed in the open field and object recognition tasks. We examined hippocampal levels of interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), as proinflammatory markers, and occludin, a protein known to regulate BBB permeability. Iron-exposed animals showed impaired recognition memory, with elevated TNF-α and IL-1β, while CBD reversed memory deficits and reduced IL-1β in iron-treated animals, without affecting TNF-α. CBG restored memory, decreased IL-1β in both iron-treated and controls, and increased TNF-α in controls. Also, iron overload reduced occludin expression in vehicle-treated rats which was reversed by both CBD and CBG. These findings highlight inflammation and BBB disruption as mediators of iron-induced cognitive dysfunction and show that both phytocannabinoids act through distinct but complementary mechanisms, supporting their therapeutic potential in neuroinflammation linked to iron overload.
- 28 August 2026
- Published by Springer Nature in Neurotoxicity Research
- Vol. 44 (5) , 48
Open AccessDifferential Effects of Cannabidiol and Cannabigerol on Cognition, Neuroinflammation, and Blood–Brain Barrier Integrity in a Rat Model of Iron Overload
Iron is an essential micronutrient for brain development, participating in mitochondrial respiration, myelination, and neurotransmitter synthesis. However, previous studies have demonstrated that excessive iron during early postnatal life induces oxidative reactions, leading to mitochondrial dysfunction and synaptic failure. These alterations compromise energy metabolism and neuronal integrity, contributing to long-lasting cognitive dysfunction and increased brain vulnerability later in life. This study evaluated the effects of cannabidiol (CBD) and cannabigerol (CBG) on behavioral, neuroinflammatory, and blood-brain barrier (BBB) outcomes in rats exposed to early-life iron overload. Male Wistar rats received iron carbonyl (30 mg/kg, intragastrically) from postnatal day 12 to 14. At three months of age, they were treated intraperitoneally with CBD, CBG (both at 10 mg/kg), or vehicle for 21 days. Cognitive performance was assessed in the open field and object recognition tasks. We examined hippocampal levels of interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), as proinflammatory markers, and occludin, a protein known to regulate BBB permeability. Iron-exposed animals showed impaired recognition memory, with elevated TNF-α and IL-1β, while CBD reversed memory deficits and reduced IL-1β in iron-treated animals, without affecting TNF-α. CBG restored memory, decreased IL-1β in both iron-treated and controls, and increased TNF-α in controls. Also, iron overload reduced occludin expression in vehicle-treated rats which was reversed by both CBD and CBG. These findings highlight inflammation and BBB disruption as mediators of iron-induced cognitive dysfunction and show that both phytocannabinoids act through distinct but complementary mechanisms, supporting their therapeutic potential in neuroinflammation linked to iron overload.
- 20 July 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (7) , e70234
Effects of cannabidiol in comparison to hormonal therapy on estrogen decline‐induced memory impairments and endocannabinoid system in rats
The aim of this study was to investigate the effects of cannabidiol (CBD) on memory deficits induced by ovariectomy and to directly compare its effects with those of hormone therapy, in order to better understand potential shared mechanisms related to menopause‐associated cognitive decline, with a particular focus on the endocannabinoid system. Three‐month‐old female Wistar rats were randomly assigned to four experimental groups: SHAM‐Veh (Vehicle), OVX‐Veh, OVX‐E2 (estradiol), and OVX‐CBD. Animals underwent either bilateral ovariectomy or sham surgery. Following a three‐week recovery period, rats received daily subcutaneous injections of CBD (10 mg/kg), estradiol (10 μg/kg), or vehicle for 21 consecutive days. Behavioral assessments included object recognition and fear‐motivated memory tests. Twenty‐four hours after the final treatment, animals were euthanized for neurochemical and molecular analyses. Levels of the endocannabinoids anandamide (AEA) and 2‐arachidonoylglycerol (2‐AG) were measured using high‐performance liquid chromatography. Gene expression of cannabinoid receptors CB1 and CB2, as well as enzymes involved in the synthesis and degradation of endocannabinoids (NAPE‐PLD, DAGL‐A, FAAH, and MGLL), was evaluated in the hippocampus by RT‐qPCR. The results demonstrated that CBD treatment produced memory improvements in the object recognition task comparable to those observed with estradiol. Ovariectomy‐induced impairments in fear‐motivated memory were completely reversed by both CBD and estradiol treatments. Additionally, CBD reduced the expression of FAAH and MGLL, resulting in increased hippocampal levels of AEA and 2‐AG, effects similar to those observed with hormone therapy. Estradiol also increased NAPE‐PLD expression, contributing to elevated AEA levels. Overall, the findings suggest that CBD exerts a protective effect on memory comparable to standard estrogen therapy, supporting its therapeutic potential for menopause‐related cognitive impairments.
- 20 July 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (7) , e70234
Effects of cannabidiol in comparison to hormonal therapy on estrogen decline‐induced memory impairments and endocannabinoid system in rats
The aim of this study was to investigate the effects of cannabidiol (CBD) on memory deficits induced by ovariectomy and to directly compare its effects with those of hormone therapy, in order to better understand potential shared mechanisms related to menopause‐associated cognitive decline, with a particular focus on the endocannabinoid system. Three‐month‐old female Wistar rats were randomly assigned to four experimental groups: SHAM‐Veh (Vehicle), OVX‐Veh, OVX‐E2 (estradiol), and OVX‐CBD. Animals underwent either bilateral ovariectomy or sham surgery. Following a three‐week recovery period, rats received daily subcutaneous injections of CBD (10 mg/kg), estradiol (10 μg/kg), or vehicle for 21 consecutive days. Behavioral assessments included object recognition and fear‐motivated memory tests. Twenty‐four hours after the final treatment, animals were euthanized for neurochemical and molecular analyses. Levels of the endocannabinoids anandamide (AEA) and 2‐arachidonoylglycerol (2‐AG) were measured using high‐performance liquid chromatography. Gene expression of cannabinoid receptors CB1 and CB2, as well as enzymes involved in the synthesis and degradation of endocannabinoids (NAPE‐PLD, DAGL‐A, FAAH, and MGLL), was evaluated in the hippocampus by RT‐qPCR. The results demonstrated that CBD treatment produced memory improvements in the object recognition task comparable to those observed with estradiol. Ovariectomy‐induced impairments in fear‐motivated memory were completely reversed by both CBD and estradiol treatments. Additionally, CBD reduced the expression of FAAH and MGLL, resulting in increased hippocampal levels of AEA and 2‐AG, effects similar to those observed with hormone therapy. Estradiol also increased NAPE‐PLD expression, contributing to elevated AEA levels. Overall, the findings suggest that CBD exerts a protective effect on memory comparable to standard estrogen therapy, supporting its therapeutic potential for menopause‐related cognitive impairments.